Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Allopurinol after primary PCI for acute anterior STEMI
IRCT20140512017666N2Phase 3Completed
- Sponsor
- Tabriz University of Medical Sciences
- Start
- Feb 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of allopurinol in myocardial infarction (MI) and acute ST-segment elevation myocardial infarction (STEMI) (2 arms), sponsored by Tabriz University of Medical Sciences. Primary endpoints: Intra-hospital major adverse cardiovascular events, Ischemic stroke and 2 more. Started Feb 2019; status: completed.
02
Drugs
allopurinol
03
Conditions
myocardial infarction (MI)acute ST-segment elevation myocardial infarction (STEMI)
Beyond the preview
Go deeper on IRCT20140512017666N2.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20140512017666N2.